Literature DB >> 22392900

The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-α1C.

Lei Guo1, Zhaoping Qiu, Liuping Wei, Xiufeng Yu, Xu Gao, Shulin Jiang, Hai Tian, Chun Jiang, Daling Zhu.   

Abstract

Chronic hypoxia is the most common cause of secondary pulmonary hypertension, for which the mechanisms are still unclear. Recent studies implicated an important role for microRNAs (miRNAs) in hypoxia-mediated responses in various cellular processes, including cell apoptosis and proliferation. Therefore, we hypothesized that these regulatory molecules might be implicated in the etiology of hypoxic pulmonary hypertension. Here we show that miRNA-328, a posttranscriptional regulator, was drastically downregulated in the pulmonary artery (PA) after a hypoxic assault. PA rings, Western blot, quantitative real-time PCR, in situ hybridization, and luciferase assay were used to investigate the role of miRNA-328 in hypoxic pulmonary hypertension. We found that hypoxia produced a significant inhibition of miRNA-328 expression, which was involved in PA vasoconstriction and remodeling. Overexpressing miRNA-328 in the transgenic mice remarkably decreased the right ventricular systolic pressure and PA wall thickness under both normoxia and hypoxia. MiRNA-328 inhibited L-type calcium channel-α1C expression through a miRNA-328 binding site within the 3' untranslational region of L-type calcium channel-α1C. The L-type calcium channel-α1C inhibition attenuated the PA response to KCl. Furthermore, miRNA-328 suppressed the insulin growth factor 1 receptor, ultimately leading to apoptosis of pulmonary arterial smooth muscle cells. The posttranscriptional repression of L-type calcium channel-α1C and insulin growth factor 1 receptor was further confirmed by luciferase reporter assay. These results showed that miRNA-328, an important protecting factor, plays a significant role in PA constriction and remodeling by regulating multiple gene targets in hypoxic pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392900     DOI: 10.1161/HYPERTENSIONAHA.111.185413

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  64 in total

Review 1.  Epigenetics: novel mechanism of pulmonary hypertension.

Authors:  Jing-bin Huang; Jian Liang; Xiao-fang Zhao; Wen-sen Wu; Fu Zhang
Journal:  Lung       Date:  2013-09-20       Impact factor: 2.584

Review 2.  Mechanisms and therapeutic potential of microRNAs in hypertension.

Authors:  Lijun Shi; Jingwen Liao; Bailin Liu; Fanxing Zeng; Lubo Zhang
Journal:  Drug Discov Today       Date:  2015-05-21       Impact factor: 7.851

Review 3.  Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles.

Authors:  Nathan R Tykocki; Erika M Boerman; William F Jackson
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

4.  Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.

Authors:  Jared M McLendon; Sachindra R Joshi; Jeff Sparks; Majed Matar; Jason G Fewell; Kohtaro Abe; Masahiko Oka; Ivan F McMurtry; William T Gerthoffer
Journal:  J Control Release       Date:  2015-05-13       Impact factor: 9.776

5.  MiR-449a-5p mediates mitochondrial dysfunction and phenotypic transition by targeting Myc in pulmonary arterial smooth muscle cells.

Authors:  Chen Zhang; Cui Ma; Lixin Zhang; Linlin Zhang; Fengying Zhang; Mingfei Ma; Xiaodong Zheng; Min Mao; Tingting Shen; Daling Zhu
Journal:  J Mol Med (Berl)       Date:  2019-02-04       Impact factor: 4.599

6.  Hypoxamirs and mitochondrial metabolism.

Authors:  Katherine A Cottrill; Stephen Y Chan; Joseph Loscalzo
Journal:  Antioxid Redox Signal       Date:  2014-02-03       Impact factor: 8.401

7.  Hypoxia induces downregulation of soluble guanylyl cyclase β1 by miR-34c-5p.

Authors:  Xiaojian Xu; Shumin Wang; Juan Liu; Dou Dou; Limei Liu; Zhengju Chen; Liping Ye; Huixia Liu; Qiong He; J Usha Raj; Yuansheng Gao
Journal:  J Cell Sci       Date:  2012-10-04       Impact factor: 5.285

Review 8.  OxymiRs in cutaneous development, wound repair and regeneration.

Authors:  Chandan K Sen; Sashwati Roy
Journal:  Semin Cell Dev Biol       Date:  2012-10-10       Impact factor: 7.727

Review 9.  Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect.

Authors:  Katherine A Cottrill; Stephen Y Chan
Journal:  Eur J Clin Invest       Date:  2013-04-26       Impact factor: 4.686

10.  Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p.

Authors:  Salil Sharma; Soban Umar; Francois Potus; Andrea Iorga; Gabriel Wong; David Meriwether; Sandra Breuils-Bonnet; Denise Mai; Kaveh Navab; David Ross; Mohamad Navab; Steeve Provencher; Alan M Fogelman; Sébastien Bonnet; Srinivasa T Reddy; Mansoureh Eghbali
Journal:  Circulation       Date:  2014-06-24       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.